PIN Stock News India Powershares (PIN) 21.38 08/02/2014 04:3

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
India Powershares (PIN) 21.38 $PIN

PowerShares India Portfolio Shares Up 20.7% Since SmarTrend's Buy Recommendation (PIN)
Comtex SmarTrend(R) - Fri Aug 01, 9:58AM CDT
SmarTrend identified an Uptrend for PowerShares India Portfolio (NYSEIN) on December 9th, 2013 at $17.72. In approximately 8 months, PowerShares India Portfolio has returned 20.69% as of today's recent price of $21.38.

PowerShares India Portfolio Has Returned 23.4% Since SmarTrend Recommendation (PIN)
Comtex SmarTrend(R) - Fri Jul 25, 9:18AM CDT
SmarTrend identified an Uptrend for PowerShares India Portfolio (NYSEIN) on December 9th, 2013 at $17.72. In approximately 8 months, PowerShares India Portfolio has returned 23.40% as of today's recent price of $21.86.

PowerShares India Portfolio Has Returned 18.9% Since SmarTrend Recommendation (PIN)
Comtex SmarTrend(R) - Thu Jul 17, 5:26PM CDT
SmarTrend identified an Uptrend for PowerShares India Portfolio (NYSEIN) on December 9th, 2013 at $17.72. In approximately 7 months, PowerShares India Portfolio has returned 18.88% as of today's recent price of $21.06.

Uptrend Call Working As PowerShares India Portfolio Stock Rises 19.7% (PIN)
Comtex SmarTrend(R) - Thu Jul 10, 11:12AM CDT
SmarTrend identified an Uptrend for PowerShares India Portfolio (NYSEIN) on December 9th, 2013 at $17.72. In approximately 7 months, PowerShares India Portfolio has returned 19.67% as of today's recent price of $21.20.

PowerShares India Portfolio Up 24.1% Since SmarTrend Uptrend Call (PIN)
Comtex SmarTrend(R) - Thu Jul 03, 9:46AM CDT
SmarTrend identified an Uptrend for PowerShares India Portfolio (NYSEIN) on December 9th, 2013 at $17.72. In approximately 7 months, PowerShares India Portfolio has returned 24.08% as of today's recent price of $21.98.

Bear Market for India ETFs Following Modi's Election? - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jun 19, 9:00AM CDT
Investors are facing a bear market in India ETFs following the election of Modi as Prime Minister.

23.8% Return Seen to Date on SmarTrend PowerShares India Portfolio Call (PIN)
Comtex SmarTrend(R) - Wed Jun 11, 11:06AM CDT
SmarTrend identified an Uptrend for PowerShares India Portfolio (NYSEIN) on December 9th, 2013 at $17.72. In approximately 6 months, PowerShares India Portfolio has returned 23.85% as of today's recent price of $21.94.

PowerShares India Portfolio Shares Up 18.3% Since SmarTrend's Buy Recommendation (PIN)
Comtex SmarTrend(R) - Wed May 28, 9:22AM CDT
SmarTrend identified an Uptrend for PowerShares India Portfolio (NYSEIN) on December 9th, 2013 at $17.72. In approximately 6 months, PowerShares India Portfolio has returned 18.26% as of today's recent price of $20.95.

India ETF in Focus on Recent Rate Hike - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Sun Feb 02, 10:47AM CST
Can India turn around their luck following a recent rate hike?

3 Emerging Market ETFs to Watch for Political Issues in 2014 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Dec 30, 11:01AM CST
These emerging market ETFs could be rocked by politics in 2014.

Can India ETFs Rebound in 2014? - ETF News And Commentary
Zacks Equity Research - ZACKS - Tue Dec 17, 11:03AM CST
A combination of internal and external factors led to a small rally in India ETFs; can it continue?

India ETFs--Is the Worst Over? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 11, 9:00AM CDT
After a steep sell-off, some of these ETFs are worth a look from long term perspective.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 3

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 2

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 2

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 2

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 7

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 4

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Discovering High-Yield Dividend Opportunities Today

Updated Category News Views 46

Ares Capital got traders buzzing back when it offered a solid yield of around 9%. It stood out as the largest publicly traded business development company (BDC) globally, which made income-focused investors take notice. But here’s the kicker: BDCs like Ares can sidestep corporate taxes if they hand out most of their earnings as dividends, creating a prime hunting ground...

Continue Reading
Anthony DiSilvestro Joins Keurig Dr Pepper as CFO

Updated Category News Views 175

Keurig Dr Pepper Welcomes New Chief Financial Officer Keurig Dr Pepper (NASDAQ: KDP) recently announced an exciting leadership change with the appointment of Anthony DiSilvestro as its new Chief Financial Officer. This important transition marks a significant step as DiSilvestro steps into his role immediately, bringing over four decades of extensive experience across...

Continue Reading
Elisa's New Branding: Introducing Elisa Industriq for Growth

Updated Category News Views 237

Elisa Unveils Elisa Industriq: A New Era in Software Solutions Elisa Oyj is excited to announce a significant milestone as it consolidates its international digital services under a unified brand known as Elisa Industriq. This initiative aims to streamline its software offerings and create a robust identity within the market. Following this change, Elisa will report the...

Continue Reading
Illinois American Water Backs United Way with Grants

Updated Category News Views 15

Driving Community Support Through Strategic Grants The American Water Charitable Foundation and Illinois American Water are making waves by putting their money where their mouth is, delivering a batch of state strategic impact grants to United Way organizations that promise to spark some serious change. It’s not every day you see such a duo diving into local communities...

Continue Reading
Essity Faces Early Bond Repayment Demand Amid Dispute

Updated Category News Views 43

Essity Faces Early Bond Repayment Demand Amid Dispute Essity has found itself in a challenging situation. Recently, a handful of bondholders have made a demand for the early repayment of bonds that are set to mature in the upcoming years of 2029, 2030, and 2031. This unexpected request has prompted Essity to reaffirm its position and contest the claims of these...

Continue Reading